Trial Profile
Phase II Study Of Single-Agent SU011248 In The Second-Line Treatment Of Patients With Metastatic Renal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Nov 2016
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 14 Nov 2016 New trial record.